4:25 PM
 | 
Aug 08, 2018
 |  BC Extra  |  Company News

Sarepta bolsters gene therapy pipeline through deal with Lacerta

Sarepta Therapeutics Inc. (NASDAQ:SRPT) gained exclusive rights to an undisclosed preclinical gene therapy to treat Pompe disease from Lacerta Therapeutics Inc. (Alachua, Fla.), as well as options to two additional CNS gene therapy candidates.

Lacerta will receive $8 million up front and a $30 million equity investment from Sarepta. The company...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >